Pharmaceutical statistics

In the area of pharmaceutical statistics, members of Smu have been collaborating with the companies of the like of Pfizer and GlaxoSmithKline, as well as with their colleagues in other universities. There are three particular areas of interest in pharmaceutical statistics where memebers of Smu feel especially confident:

Cardiff Investigators


Selected publications

  1. Jones C.M., Zhigljavsky A.A. (2001) Comparison of costs for multi-stage group testing methods in the pharmaceutical industry, Communication in Statistics - Theory and Methods, 30, 2189-2209.
  2. Bond B., Fedorov V.V., Jones C.M., and Zhigljavsky A.A.(2001) Pharmaceutical applications of the multi-stage group testing, in: Optimum Design - 2000 (Atkinson A.C., Bogacka B., Zhigljavsky A.A., eds.), Kluwer Academic Publishers, 155-166.
  3. Zhigljavsky A. (2010) Nonadaptive group testing with lies: Probabilistic existence theorems. Journal of Statistical Planning and Inference, v. 140, No. 10, 2825 – 2893.
  4. Fedorov, V., Jones, B., Jones, C. M., Zhigljavsky, A. (2004) Estimation of the treatment difference in multicenter trials. J. Biopharm. Statist. 14, no. 4, 1037-1063.
  5. Fedorov, V., Jones, B., Jones, C. M., Zhigljavsky, A. (2005) Multi-center clinical trials with random enrollment: theoretical approximations. Comm. Statist. Theory Methods 34, no. 4, 955--985.
  6. Fedorov, V., Jones, B., Savani V. , Zhigljavsky, A. (2007) Deriving approximations in a random effects model for multicentre clinical trials with binary response. Communications in Statistics: Theory and Methods, v. 37. No. 3, 629-644.
  7. Dette H., Pepelyshev A., Shpilev P., Wong W.K. (2009) Optimal designs for discriminating between dose response models in toxicology studies. Bernoulli 16, 1164–1176.
  8. Dette H., Pepelyshev A., Wong W.K. (2009) Optimal designs for dose-finding experiments in toxicity studies. Bernoulli, 15, 124-145.
  9. Dette H., Bretz F., Pepelyshev A., Pinheiro J. (2008) Optimal designs for dose-finding studies. J. Amer. Statist. Assoc. 103, no. 483, 1225-1237.